NCT06656390 2026-03-06
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT07269145 2026-01-28
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT04495296 2025-12-19
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT06662760 2025-11-25
Clinical Trial of TQB3002 in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT06092580 2025-09-02
Phase 1 Study of AWT020 in Advanced Cancer
Anwita Biosciences
Phase 1 Recruiting
NCT06963814 2025-07-17
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
HC Biopharma Inc.
Phase 1 Recruiting
NCT05276310 2025-06-27
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
Phase 1 Recruiting
NCT06707610 2025-03-12
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1 Recruiting
NCT05894421 2024-03-12
TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting